Skip to main content

Table 2 Direct treatment utilization and costs for patients that remained in care for one full year (n = 169)

From: The cost of antiretroviral therapy in Haiti

  Mean utilization per patient for the 1st year of ART Median utilization (IQ range) per patient for the 1st year of ART Mean cost per patient for the 1st year of ART ($US) Median cost (IQ range) per patient for the 1st year of ART ($US)
Pre-ART workup (labor and laboratory studies) * * 58 61 (61 to 61)
Labor cost (# of ART visits) 14.9 15 (14 to 16) 59 54 (47 to 63)
CD4 cell counts** (# of tests) 1.3 1 (1 to 2) 39 30 (30 to 60)
ART monitoring labs (# of tests) 11.3 11 (9 to 13) 85 85 (68 to 99)
TB tests (# of tests) 1.8 0 (0 to 3) 8 0 (0 to 14)
Other laboratory tests (# of tests) 3.2 2 (1 to 4) 9 8 (2 to 13)
Chest radiographs (# of x-rays) 0.4 0 (0 to 1) 10 0 (0 to 24)
Anti-retroviral therapy (# of days on ART) 357 367 (355 to 379) 439 413 (273 to 601)
TB medications (# of days on therapy) 21 0 (0 to 0) 6 0 (0 to 0)
Other medications*** * * 37 31 (21 to 42)
Outside referrals 0.4 0 (0 to 0) 39 0 (0 to 19)
Hospitalizations 0.05 0 (0 to 0) 35 0 (0 to 0)
Telephone cards 2.4 3.2 (2 to 3) 3 4 (3 to 4)
Nutritional support * * 145 160 (100 to 200)
Total (# of days in care) 364 365 (365 to 365) 972 923 (770 to 1098)
  1. IQ range = interquartile range
  2. * No utilization units defined.
  3. ** This does not include the baseline CD4 cell count done before the initiation of ART; also, many patients had a 12-month CD4 cell count that was done more than 365 days after ART initiation, and was therefore excluded from the analysis.
  4. *** GHESKIO paid a mean cost of US$33.69 per patient for other medications (i.e. not including ART or TB drugs). The mean cost per patient for medications purchased outside of GHESKIO was $US 4.31 (median cost of $US 1.23).
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us